Lucentis® is an injectable treatment for patients suffering from wet AMD. As an anti-VEGF drug, Lucentis® can both treat and slow the progression of age-related macular degeneration. Lucentis® restricts the growth of abnormal blood vessels, which when left untreated, are responsible for causing spots and darkness in a patient’s vision. With Lucentis® treatments, patients can prevent their vision from worsening and even improve their vision.

Prior to the Lucentis® treatment, a topical anesthetic will be placed on the eye. Then, the Lucentis® formula will be injected into the eye, where it will limit the formation of harmful blood vessels. Typically, patients are encouraged to receive Lucentis® treatments starting at monthly intervals for the first few months, and can then be received at larger intervals in later months.

Lucentis® offers a quick injectable treatment for the management of wet AMD, with infrequent dosage requirements providing patients with a flexible treatment experience. Lucentis® is proven to help patients maintain their vision, with most patients achieving an improvement in their vision within two years of treatment.

Lucentis® is known to have the risk of causing eye pressure, eye pain and inflammation of the eye. Some patients may experience minor eye discomfort that resolves within a few hours of treatment. However, it is still one of the leading treatment options for patients seeking treatment for wet AMD.